Background
==========

Patients with HIV RNA suppression below 50 copies/mL may still have HIV RNA detectable by more sensitive PCR assay techniques.

Methods
=======

In the MONET trial, 256 patients with HIV RNA \<50 copies/mL on current HAART, and no history of virological failure, switched to DRV/r 800/100 mg once daily, either as monotherapy (n=127) or with 2NRTI (n=129). HIV RNA was evaluated by the Roche Amplicor Ultrasensitive assay (lower detection limit=50 copies/mL), for all patient visits to Week 96. With this assay, \"Optical Density=background\" was used to assess whether HIV RNA was detectable or undetectable below 50 copies/mL.

Results
=======

Patients were 81% male, 91% Caucasian, and had median baseline CD4 count of 575 cells/uL. At the baseline visit, the percentage of patients with HIV RNA undetectable below 50 copies/mL (OD=background) was 80% in the DRV/r mono arm and 79% in the DRV/r + 2NRTI arm. The percentage with HIV RNA at different levels at the Week 96 visit is shown in Table [1](#T1){ref-type="table"} (observed data analysis)

  HIV RNA                         DRV/r mono (n=105)   DRV/r + 2NRTIs (n=114
  ------------------------------- -------------------- -----------------------
  HIV RNA \<50, OD = background   79.0%                80.7%
                                                       
  HIV RNA \<50, detectable        17.1%                14.9%
                                                       
  HIV RNA 50-400 copies/mL        2.9%                 3.5%
                                                       
  HIV RNA \<400 copies/mL         1.0%                 0.9%
                                                       
                                                       

Including all samples from patient visits from Week 4 to Week 96, HIV RNA was above 50 copies/mL in 69/1009 samples in the DRV/r monotherapy arm (50-400: 84%, 400-1000: 12%, \>1000: 4%) and 47/1051 samples in the DRV/r + 2NRTI arm (50-400: 83%, 400-1000: 8.5%, \>1000: 8.5%).

Conclusions
===========

In this study for patients with HIV RNA \<50 copies/mL at baseline, switching to DRV/r monotherapy showed similar levels of HIV RNA suppression to DRV/r + 2NRTIs, using more sensitive PCR assay techniques.
